NCT04869137View on ClinicalTrials.gov

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions
Merkel Cell CarcinomaNeuroendocrine Carcinoma of the SkinTrabecular Carcinoma of the Skin
Interventions
DRUG

Lenvatinib Oral Product

20mg of Lenvatinib will be taken orally once daily

DRUG

Pembrolizumab

200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER